ArticleCell communication and signaling : CCS2026
Regulation of reticular adhesions by KANK2 and talin2 in two melanoma cell lines.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- KANK2 at focal adhesions regulates their maintenance and dynamics, while at fibrillar adhesions it influences cell migration via microtubule-dependent mechanism.Cell communication and signaling : CCS · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundIntegrins bind extracellular matrix proteins and, upon clustering, form multimolecular integrin adhesion complexes (IACs) that connect to and regulate the cell cytoskeleton, influencing various aspects of cell behaviour. Alongside well-characterized focal adhesions (FAs) and fibrillar adhesions (FBs), a new class of IACs, reticular adhesions (RAs), have been identified. RAs, formed by integrin αVβ5, lack actin association and classical FAs markers and their physiological role in cells remains poorly understood. Previously, we showed that two melanoma cell lines, MDA-MB-435S and RPMI-7951, preferentially use integrin αVβ5 (which can form FAs or RAs) for adhesion under long-term culture conditions. Here we investigate the composition of RAs in these two melanoma cell lines.
methodsCells were treated with the actin polymerisation inhibitor cytochalasin D to disrupt FAs and enable isolation and mass spectrometry–based analysis of RAs components. Western blotting, immunofluorescence microscopy and proximity ligation assays (PLA) were performed to assess protein expression and localization within RAs. The effects of talin2 and KN motif and ankyrin repeat domains protein 2 (KANK2) knockdown on RA composition were examined in both melanoma cell lines.
resultsKnown RA-associated proteins, including the Adaptor protein 2 (AP2) complex, disabled homolog 2 (DAB2), Numb and talin2 were identified in both lines, along with a new protein, KANK2. PLA following actin disruption confirmed the proximity of KANK2 and talin2 in RAs. Knockdown experiments demonstrated that although both talin2 and KANK2 are located in RAs, neither is essential for RA formation. Talin2 knockdown resulted in reduced abundance of RA components in both cell lines. In MDA-MB-435S cells, KANK2 knockdown produced a similar effect. However, in RPMI-7951 cells, KANK2 knockdown had no significant effect on RA components abundance, reflecting the differential localization and role of KANK2 in this cell line.
conclusionWe provide a comprehensive analysis of RAs in two melanoma cell lines and identify KANK2 as a novel RA-associated protein. The differential effects of KANK2 knockdown on the abundance of RAs underscores its distinct role in αVβ5-mediated adhesions, FAs and RAs, across the two cell lines. These findings emphasize the importance of adhesion crosstalk in regulating integrin αVβ5–mediated cell adhesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.